Burning mouth syndrome due to Efavirenz therapy [2]

Annals of Pharmacotherapy

Volumn 40, Issue 7-8, 2006, Pages 1471-1472

  Borrás Blasco, Joaquín ^a   Belda, Alberto ^a   Rosique Robles, J Dolores ^a   Casterá, Elvira ^a   Abad, F Javier ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ADULT; BURNING MOUTH SYNDROME; CASE REPORT; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BURNING MOUTH SYNDROME; FEMALE; HUMANS; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33747008411     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H036     Document Type: Letter

References (5)

1. Grushka M, Kawalec J, Epstein JB. Burning mouth syndrome: evolving concepts. Oral Maxillofac Surg Clin North Am 2000;12:287-95.
2. Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev 2005;1: CD002779.
3. Savino LB, Haushalter NM. Lisinopril-induced "scalded mouth syndrome." Ann Pharmacother 1992;26:1381-2.
4. Culhane NS, Hodle AD. Burning mouth syndrome after taking clonazepam. Ann Pharmacother 2001;35:874-6. DOI 10.1345/aph.1Z434
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.